EXTENSIVE STAGE LUNG SMALL CELL CARCINOMA

This study is for people with extensive-stage small cell lung cancer (ES-SCLC). It tests whether using specific features of a person's tumor (biomarkers) can help doctors choose the best maintenance treatment to keep the cancer under control after initial therapy. Participants wi…

This study tests whether adding the experimental drug iadademstat to standard immunotherapy (atezolizumab or durvalumab) can keep extensive-stage small cell lung cancer from growing longer than immunotherapy alone. About 45 adults whose cancer responded to initial chemoimmunother…

This study tests a drug called tarlatamab in 39 people with extensive-stage small cell lung cancer, a fast-growing cancer that has spread. Tarlatamab is a special antibody that helps the body's immune cells find and attack cancer cells. The goal is to see if it can delay cancer g…

This study is for people with extensive-stage small cell lung cancer who have already responded to initial chemo-immunotherapy. It compares standard maintenance immunotherapy (atezolizumab) alone versus adding radiation therapy to see if the combination delays cancer growth or sp…

This study tests a combination of chemotherapy (temozolomide) and immunotherapy (atezolizumab) as a second or third treatment option for people with small cell lung cancer that has spread or returned. The goal is to see if this combination can shrink tumors and help patients live…

This study tests whether adding lamivudine, an antiviral drug, to standard chemotherapy and immunotherapy can stop small cell lung cancer from becoming resistant to treatment. About 28 adults with extensive-stage small cell lung cancer will receive the combination. The goal is to…

This early-stage study tests whether giving palliative radiotherapy together with the drug lurbinectedin is safe for people with extensive-stage small cell lung cancer that has spread beyond the chest. The goal is to relieve symptoms caused by the cancer. About 22 adults whose ca…